Prostate Cancer Recurrent clinical trials

Explore recruiting prostate cancer recurrent clinical trials.

Recruiting prostate cancer recurrent studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Prostate Cancer Recurrent trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Phase I study to evaluate the safety, tolerability and preliminary efficacy of the bispecific PSMAxCD3 antibody CC 1 in men with biochemical recurrence of prostate cancer

Germany

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A randomized trial comparing conventional "salvage" radiotherapy and individualized PSMA-PET/CT targeted treatment in patients with biochemical recurrence after prostate cancer surgery

Sweden

Therapeutic confirmatory (Phase III) EU CTIS Study details

Open-label clinical phase 1/2 study to assess the safety and efficacy of the SpectraCure P18 System (Interstitial multiple diode lasers and IDOSE® Software) and verteporfin for injection (VFI) for the treatment of recurrent prostate cancer

Germany, Sweden

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A Randomized, Controlled, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer, Assessed by PSMA-PET, with an Observational Cohort

Italy, Portugal, Finland, Sweden, Spain, Denmark +7 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

DUET-study: A FEASIBILITY STUDY OF 177LU-PSMA RADIOLIGAND THERAPY ALTERNATED WITH RADIUM-223 IN PATIENTS WITH BONE-METASTATIC, OLIGO-METASTATIC HORMONE-SENSITIVE PROSTATE CANCER AFTER CURATIVE THERAPY.

Netherlands

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A Phase 1 Study of JNJ-87189401 Combined with JNJ-78278343 for Advanced Prostate Cancer

Netherlands, France

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Prostate Cancer Recurrent trials by city

Prostate Cancer Recurrent in Toronto Prostate Cancer Recurrent in Vancouver Prostate Cancer Recurrent in Montreal Prostate Cancer Recurrent in Calgary Prostate Cancer Recurrent in Edmonton Prostate Cancer Recurrent in Ottawa Prostate Cancer Recurrent in Winnipeg Prostate Cancer Recurrent in Quebec City Prostate Cancer Recurrent in Hamilton Prostate Cancer Recurrent in Kitchener Prostate Cancer Recurrent in London Prostate Cancer Recurrent in Halifax Prostate Cancer Recurrent in New York Prostate Cancer Recurrent in Los Angeles Prostate Cancer Recurrent in Chicago Prostate Cancer Recurrent in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease